What adjuvant therapy would you offer a post-menopausal CHEK2+ patient with HR+ HER2+ T1bN1 breast cancer and concurrent HR+ HER2- T1N0 disease?

I have a patient in her 60s with CHEK2 mutation, diagnosed with bilateral breast cancer. Lumpectomy showed b/l tumors <10mm both ER/PR+, HER2-, but one positive 11mm axillary sentinel node still ER/PR+, but HER2 is 3+.

Answer from: Medical Oncologist at Academic Institution

These are hard cases. In general, the HER2 positive disease will take priority. Although it would be ideal to have treated the patient neoadjuvantly to assess response and potentially offer adjuvant TDM-1 per the KATHERINE trial, for now, I would optimize her therapy with adjuvant TCHP for 6 cycles ...

Comments

Medical Oncologist at Florida Cancer Specialists and Research Institute
In our hospital, we do not normally do separate ER...

Medical Oncologist at OSF HealthCare Saint Anthony Medical Center Center For Cancer Care
@Tarah Ballinger, would your approach change if th...

Please select the option that best describes you:

What adjuvant therapy would you offer a post-menopausal CHEK2+ patient with HR+ HER2+ T1bN1 breast cancer and concurrent HR+ HER2- T1N0 disease?

Related Questions